Back to search results

Accelerated Pulmonary Rehabilitation for Lung Cancer Patients

This study is looking at an accelerated pulmonary rehabilitation (PR) program for people with chronic obstructive pulmonary disease (COPD) and suspected or confirmed lung cancer who are also current smokers. PR is a program that helps improve breathing and overall fitness. In this study, the PR program will be offered more frequently (up to 4 days a week for up to 4 weeks) than standard care, aiming for 16 sessions before surgery. The main goals are to see how many eligible patients join the study and how many PR sessions they complete. You might be able to join if you are 18 or older, have a lung nodule suspicious for cancer, are eligible for treatment, and smoke at least 5 cigarettes a day, and are willing to try to quit smoking.

Study design
This is a single-arm study, meaning all participants receive the same intervention. It aims to enroll 20 participants over approximately two years.
What's involved
You will participate in up to 16 pulmonary rehabilitation sessions over a maximum of 4 weeks. You will also complete initial assessments including demographics and health information.
Compensation
Not stated in the trial record.
Follow-up
The study will measure enrollment through its completion, approximately 2 years. Pulmonary rehab sessions completed will be measured during the 14-21 day intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06432972

Accelerated Pulmonary Rehabilitation in the Preoperative Period

Recruiting
NAAges 18+InterventionalTreatment
University of Vermont
~20 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:Pulmonary Rehab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of patients determined eligible who enroll in the study
Measured over Through study completion, approximately 2 years
+1 more outcome measured

Conditions

Chronic Obstructive Pulmonary Disease
Lung Cancer

Explore related trials

Chronic Obstructive Pulmonary DiseaseLung Carcinoma

Where it's being run

1 sites across 1 states
Vermont1

Who to contact

Olivia J Garrow, MS, RDN
[email protected]
802-847-2160
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older
Lung nodule that is deemed highly suspicious for lung cancer based on: nodule characteristics, risk factors, CT-PET avidity, previous biopsy results, and assessment by physicians specializing in lung cancers
Eligible for treatment
Current cigarette smoking ≥5 cigarettes per day
Willing to attempt smoking cessation during prehab period
Willing to take nicotine replacement therapy (NRT) and varenicline
Able to attend PR at UVMMC for 2, one-hour sequential sessions for a total of 16 sessions over 8 days during treatment
Willing and able to provide informed consent; ability determined by study physician and/or LMDC treatment physicians

Exclusion

Unable to safely participate in PR due to unstable cardiac disease, unstable peripheral vascular disease, musculoskeletal disease that would prevent exercise, significant psychiatric or neurocognitive disease that would limit ability to exercise safely in a group setting as determined by the study physician and/or treatment physicians
Inability to consistently attend PR during treatment
Pregnancy, per patient self-report
Active or recent participation in another clinical trial that, in the opinion of the investigator would impact outcomes measured in this study
Any other condition in the opinion of the investigator/study physician and or treatment physicians that would jeopardize patient safety or integrity of research results

What this trial measures

  • Proportion of patients determined eligible who enroll in the studyThrough study completion, approximately 2 years

    Acceptability and feasibility will be documented by percent of those eligible enrolling in the study.

  • Average Pulmonary Rehab sessions completedThe 14 day (up to 21 day) intervention period

    Acceptability and feasibility will be determined by the proportion of pulmonary rehab sessions completed during this condensed pulmonary rehab program